




RealRate

PHARMACEUTICAL 2014

Cubist Pharmaceuticals INC
Rank 128 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 5.4% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	869,769
Cost of Goods Sold	260,310
Intangible Assets	1,104,084
Liabilities, Current	310,828
Liabilities, Non-Current	31,726
Other Assets	994,424
Other Compr. Net Income	274
Other Expenses	6,969
Other Liabilities	1,409,536
Other Net Income	-70,054
Other Revenues	1,054,442
Property and Equipment	177,544
Research and Development	477,740
Selling, General and Administrative Expense	257,940

Output Variable	Value in 1000 USD
Assets	3,145,821
Liabilities	1,752,090
Expenses	1,002,959
Revenues	1,054,442
Stockholders Equity	1,393,731
Net Income	-18,571
Comprehensive Net Income	-18,434
BaseVar	3,512,820
ECR before LimitedLiability	123%
Economic Capital Ratio	248%